What s New in the Treatment of Psoriasis
|
|
- Berniece Garrett
- 5 years ago
- Views:
Transcription
1 What s New in the Treatment of Psoriasis Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai
2 Mark Lebwohl is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen / Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer and ViDac. Dr. Lebwohl is also a consultant for Allergan, Leopharma, and Promius.
3 Tildrakizumab Guselkumab Tremfya Brodalumab Siliq Ixekizumab Taltz Secukinumab Cosentyx Ustekinumab Stelara Adalimumab Humira Etanercept Enbrel Apremilast Otezla Certolizumab - Cimzia Tofacitinib Xeljanz Bimekizumab Risankizumab/Mirikizumab
4 Responders (%) Responders (%) PASI 75 Response Over Time resurface 1 resurface TIL 1 mg TIL 2 mg Placebo TIL 1 mg Placebo TIL 2 mg TIL1 64% TIL2 62% TIL 1: 64% * TIL 2: 62% * PBO/TIL2 86% TIL1 82% PBO/TIL 2: 86% TIL 2: 82% 1: 8% * PBO/TIL TIL2 1: 8% 77% PBO/TIL1 77% TIL 1 mg TIL 2 mg Placebo TIL 1 mg Placebo TIL 2 mg ETN TIL 2: 66% * TIL 1: 61% * ETN: 48% TIL 1: 74 PBO/TIL 2: 74% TIL 2: 74 PBO/TIL 1: 58% ETN: 56% PBO 3% PBO: 6% Weeks Weeks *P<.1 vs PBO; P<.5 vs ETN; P<.1 vs ETN; P-values unadjusted for multiplicity. P-values were calculated using the Cochran-Mantel-Haenszel (CMH) test stratified by body weight ( 9kg, >9kg) and prior exposure to biologic therapy for psoriasis. Modified intention-to-treat population (ie, all randomized patients who received 1 dose of study medication). The figure represents observed data only; data shown for Week 12 are based on missing data being imputed as non-responders. PBO=placebo; TIL=tildrakizumab; ETN=etanercept.
5 Patients (%) resurface 1 and 2: Overall efficacy after 2 years of treatment resurface 1 w.64 resurface 2 w TIL 1 mg (n=219) TIL 2 mg (n=255) FAS (full analysis set; subjects with 1 dose of extension treatment based on assigned treatment); as observed data Patients entering OLE after 64 weeks (resurface 1) or 52 weeks (resurface 2) were at least partial responders (PASI 5). For resurface 1, patients had to have received active drug within 12 weeks of end of base study TIL 1 mg (n=355) TIL 2 (n=333) PASI 75 PASI 9 PASI 1 PGA (/1) Papp K, et al. EADV 217, D3T1.1H Sponsored by Merck & Co., Inc.
6 Percentage of Patients Voyage 1 Guselkumab PASI 75 Responders: 1 Week 16 P<.1 vs. ADA 91.2 Week 24 P<.1 vs. ADA 91.2 Week 48 P<.1 vs. ADA Weeks Guselkumab (n=329) Placebo Guselkumab (n=174) Adalimumab (n=334) 7 A. Blauvelt, et al. FCD 216.
7 Patients (%) Patients (%) VOYAGE1: PASI 9 & PASI 1 response with guselkumab through 2 years GUS Placebo ADA PASI 9 PASI 1 GUS GUS NRI= Weeks n= n= n= GUS Placebo ADA GUS GUS NRI= Weeks n= n= n= Griffiths CEM, et al. EADV 217, D3T1.I Sponsored by Janssen Research and Development LLC
8 RESULTS % of Patients ACR 2/5/7 Responses at Week 24 1 Primary Endpoint 8 6 p< p=.2 p=.23 (post hoc) ACR2 ACR5 ACR7 Placebo (n=49) Guselkumab (n=1) Gottlieb A, et al. AAD 217. P4454.
9 % of Patients RESULTS Percent of Patients with Resolution of Enthesitis at Week 24 in Patients with Enthesitis at Baseline p= Placebo (n=31) Guselkumab (n=76) Enthesitis assessed by Leeds Enthesitis Index (LEI) Median % improvement in LEI at Week 24: 1% in guselkumab vs 33.3% in placebo (p=.9) Gottlieb A, et al. AAD 217. P4454.
10 % of Patients RESULTS Percent of Patients with Resolution of Dactylitis at Week 24 in Patients with Dactylitis at Baseline p= Placebo (n=23) Guselkumab (n=58) Presence and severity of dactylitis in hands/feet assessed by investigators using a -3 scale (none [], mild [1], moderate [2], severe [3]) Median % improvement in dactylitis at Week 24: 1% in guselkumab vs 33.3% in placebo (p<.1) Gottlieb A, et al. AAD 217. P4454.
11 Efficacy of brodalumab for moderate to severe psoriasis through 5 years Patients (%) Mean improvement (%) Week spga /1 response 84.8 spga spga Pts off treatment a n= Week Improvement in PASI score and % BSA PASI BSA Pts off treatment a n= a At week 264, patients had been off treatment for 6 weeks Papp K, et al. EADV 217, P1798 Sponsored by LEO Pharma
12 Patients (%) PASI responses with brodalumab over 5 years 1 Patients off treatment a 8 6 PASI 75 PASI 9 PASI Week n= As observed data Amendment (at Week 59): 65% of patients (118/181) had dose decreased from 21 to 14 mg Efficacy is maintained for up to 5 years a At week 264, patients had been off treatment for 6 weeks. Error bars represent 95% CI Papp K, et al. EADV 217, P1798 Sponsored by LEO Pharma Amendment (at Week 123): 17% of patients (3/181) had dose increased back to 21 mg due to inadequate response
13 IXORA-P: Efficacy and safety of continuous 2-weekly dosing of ixekizumab over 52 weeks in patients with moderate to severe psoriasis Patients (%) Patients (%) Screening R IXORA-P: study design Blinded treatment dosing period Week N=1227 2:1:1 IXE q2w (n=611) IXE q2w IXE q4w/ixe q2w (n=36) Dose adjustment per protocol a IXE q4w (n=31) IXE q2w is better at Week 52 *P<.5; P<.1; P<.1 vs IXE q4w a Dose adjustment based on achievement of spga 2 at 2 consecutive visits during Week 12 through Week 4; investigators were blinded to the predefined criteria and timing Langley RG, et al. EADV 217, OP4.3 Sponsored by Eli Lilly and Company Followup spga (/1) and PASI 75 responses at Week 52 (NRI) IXE q4w (n=31) IXE q4w/ixe q2w (n=36) spga (/1) PASI 75 IXE q2w (n=611) PASI 9 and PASI 1 responses at Week 52 (NRI) * PASI 9 PASI
14 Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Mease PJ, et al Ann Rheum Dis. 217;76:79-87.
15 Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Mease PJ, et al; Ann Rheum Dis. 217;76:79-87.
16 Response (%) spga of Genitalia (,1) NRI, Blinded Treatment Period, ITT Population 7 out of 1 ixekizumab-treated patients achieved clear or almost clear genital skin at Week 12 Percentage of patients achieving clear or almost clear genital skin was significantly greater for ixekizumab as early as Week 1 1 PBO (N=74) IXE Q2W (N=75) * Week * p<.1 vs. PBO; p<.1 vs. PBO ITT=Intent-to-Treat; IXE Q2W=8 mg ixekizumab every 2 weeks; NRI=non-responder imputation; PBO=placebo; spga=static Physician s Global Assessment
17 Response (%) Gen-Itch NRS a NRI, Blinded Treatment Period, ITT Population With Baseline Gen-Itch NRS 3 6 out of 1 ixekizumab-treated patients had clinically meaningful improvements a in genital itch at Week 12 Percentage of patients achieving clinically meaningful improvement in genital itch was significantly greater for ixekizumab as early as Week 2 1 PBO (N=6) IXE Q2W (N=62) Week p<.1 vs. PBO a 3 point improvement in gen-itch NRS gen-itch NRS=genital itch numeric rating scale; ITT=Intent-to-Treat; IXE Q2W=8 mg ixekizumab every 2 weeks; NRI=non-responder imputation; PBO=placebo
18 Impact on frequency of sex! SFQ= Sexual Frequency Questionnaire Proportion of patients achieving overall spga (,1) Proportion of patients achieving a 3-point improvement in genital itch numeric rating scale (gen-itch NRS) Among patients with a baseline score of 3 Proportion of patients whose frequency of sexual activity was never or rarely limited by genital psoriasis (SFQ Item 2 score or 1) Among patients with a baseline score 2 SFQ Item 2 In the past week, how often did your genital psoriasis limit the frequency of your sexual activity? Never Rarely 1 Sometimes 2 Often 3 Always 4 gen-itch NRS=genital itch numeric rating scale; SFQ=Sexual Frequency Questionnaire; spga=static Physician s Global Assessment
19 Response (%) SFQ Item 2 Score (,1) Response Rate NRI, Blinded Treatment Period, ITT Population With Baseline SFQ Item 2 Score 2 Approximately 8 out of 1 ixekizumab-treated patients were no longer or rarely limited by the impact of genital psoriasis on frequency of sexual activity at Week 12 Percentage of patients who were no longer or rarely limited by the impact of genital psoriasis on frequency of sexual activity was significantly greater for ixekizumab as early as Week PBO (N=42) IXE Q2W (N=37) 78 6 * Week p<.5 vs. PBO; * p<.1 vs. PBO; p<.1 vs. PBO ITT=Intent-to-Treat; IXE Q2W=8 mg ixekizumab every 2 weeks; NRI=non-responder imputation; PBO=placebo; SFQ=Sexual Frequency Questionnaire
20 Patients (%) SCULPTURE: Long-term skin improvement responses with secukinumab 3 mg fixed interval (q4w) through 5 years Year 1 (n=162) PASI 75 (%) PASI 9 (%) PASI 1 (%) AO MI LOCF AO MI LOCF AO MI LOCF Year Year As observed (AO) Multiple imputation (MI, n=168 at each time point) LOCF (n=168 at each time point) Year 2 (n=152) Year 3 (n=139) Year 4 (n=132) Year 5 (n=122) PASI 75 Δ=~8% PASI 9 Δ=~7% PASI 1 Δ=~5% Bissonnette R, et al. EADV 217, P2223 Sponsored by Novartis Pharma AG
21 ERASURE/FIXTURE extension study: Patients without relapse after withdrawal of secukinumab treatment Patients (%) Proportion of patients without relapse a after withdrawal of SKB 1 8 SKB 15 mg/placebo (n=1) SKB 3 mg/placebo (n=12) No relapse 12 months after SKB discontinuation 6 1 No relapse in 24 months after SKB discontinuation a Relapse: >5% loss of previous gain in PASI reduction Lebwohl M, et al. EADV 217, OP4.6 Sponsored by Novartis Pharma AG
22 Patients (%) FUTURE 2: Resolution of dactylitis and enthesitis through 2 years Resolution of dactylitis and enthesitis 1 SKB 15 mg/placebo (n=1) SKB 3 mg/placebo (n=1) Similar responses with 3 mg and 15 mg, but 3 mg better in TNF inhibitor-refractory patients 4 Efficacy of the two doses should also be compared in obese patients Week 52 Week 14 Week 52 Week 14 Dactylitis Enthesitis Gottlieb AB, et al. EADV 217, P375 Sponsored by Novartis Pharma AG
23 Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. Landells I, et al. J Am Acad Dermatol. 215;73(4):
24 Ustekinumab package insert 25 Business Use Only
25 Ustekinumab as therapy for psoriasis in a 2-year-old girl. Min MS, et al. J Eur Acad Dermatol Venereol. 216;3(11):e19-1.
26 Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA. J Am Acad Dermatol. 218 Jan;78(1):9-99.
27
28 Long-term safety/efficacy of ADA for pediatric patients with chronic plaque psoriasis Percentage achieving PASI MTX PerA, n=37 ADA.8 PerD, n=36 ADA.8 PerA, n=39 ADA.8 PerD, n=36 ADA.4 PerA, n=38 ADA.4 PerD, n= Week 16A D 1D 4D 8D 11D 16D 2D 28D 4D 52D 1 Percentage achieving PASI Week 16A D 1D 4D 8D 11D 16D 2D 28D 4D 52D Week Papp KA, et al. EADV 215, FC2.4 Sponsored by AbbVie Inc.
29 Etanercept treatment for children and adolescents with plaque psoriasis. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I,Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept PediatricPsoriasis Study Group. N Engl J Med. 28;358: Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, Collier DH, Kricorian G, Langley RG J Am Acad Dermatol. 216;74:28-7.
30 5-year efficacy of ETN in children and adolescents with plaque psoriasis PASI responses (as observed) PASI 75 responses by BMI category (as observed) Paller AS, et al. EADV 215, FC2.5 Largest and longest pediatric study with biologics in psoriasis reported to date
31 UNVEIL: 52-week efficacy and safety of apremilast in systemic- and biologic-naïve patients with moderate plaque psoriasis 5 Screening Placebo-controlled phase Week APR 3 mg bid (n=148) R 1:2 Placebo (n=73) Primary end point: Mean % change in PGA BSA at Week 16 Open-label treatment phase APR 3 mg bid (n=64) BSA involvement of 5% to 1%, naïve to systemic and biologic therapy Safety observation spga of 3 (moderate) based on a to 5 scale Placebo (n=73) Apremilast (n=148) Age (years) 51.1 ± ±15.4 Male 41 (56.2) 74 (5.) BMI (kg/m 2 ) 3.8 ± ±7.4 Duration of psoriasis (years) 13.9 ± ±13.9 PGA BSA score 21.6 ± ±5.3 % BSA 7.1 ± ±1.6 PASI score ( 72) 8. ± ±4. DLQI total score 11.1 ± ±6.5 Prior topical therapy 59 (8.8) 122 (82.4) Data are mean ±SD or n (%) At baseline, >8% of patients had received topical therapy before enrollment Strober B, et al. EADV 217, FC2.8 Sponsored by Celgene Corporation
32 UNVEIL: PGA BSA-75 and spga /1 response at Week 52 with apremilast in patients with moderate psoriasis Patients (%) Patients (%) 1 PGA BSA-75 response at Week 52 (LOCF) Placeb o n= * APR Placebo/AP n=147 R Week 16 n=64 Week 52 APR/APR n= spga /1 response (LOCF) 9.6 Placebo n=73 * APR Placebo/AP n=148 R Week 16 n=64 Week 52 APR/APR n=148 *P=.1 vs placebo from 2-sided Cochran-Mantel-Haenszel test stratified by site; LOCF was used to impute missing values. Error bars represent 95% CI Strober B, et al. EADV 217, FC2.8 Sponsored by Celgene Corporation
33 UNVEIL: Improvement in nails and scalp with apremilast at Week 52 in patients with moderate psoriasis Mean change from baseline (%) Characteristic Scalp psoriasis a (n=167) Nail psoriasis a (n=83) Placebo (n=55) APR (n=112) Placebo (n=27) Mild nail diseases used target nail NAPSI difficult to compare with other studies Caveat scalp ScPGA had successes already in the baseline Increased attention to the moderate population is necessary as DLQI in some subsets is rather high Jackson JM, et al. EADV 217, P1946 Sponsored by Celgene Corporation APR (n=56) % BSA 7.2 ± ± ± ±1.6 spga score=3 (moderate) b 53 (96.4) 11 (98.2) 26 (96.3) 55 (98.2) PASI score ( 72) 8.1 ± ± ± ±2.9 DLQI total score 1.9 ± ± ± ±5.9 ScPGA score (clear) 1 (minimal) 2 (mild) 3 (moderate) 4 (severe) 5 (very severe) 8 (14.5) 17 (3.9) 24 (43.6) 6 (1.9) 6 (5.4) 38 (33.9) 61 (54.5) 7 (6.3) 1 (3.7) 3 (11.1) 9 (33.3) 9 (33.3) 1 (3.7) 2 (3.6) 16 (28.6) 23 (41.1) 2 (3.6) NAPSI total score 4.8 ± ± ± ±2. Data are mean ±SD or n (%) a 65 patients had both scalp and nail psoriasis (22 placebo, 43 APR); b 4 patients with spga=4 enrolled in error Patients (%) d Placebo (n=27) Placebo (n=55) NAPSI score c Week 16 Week 52 APR (n=56) Placebo/APR (n=23) ScPGA /1 response P=.178 APR (n=112) APR/APR (n=48) Placebo/APR (n=49) Week 16 Week 52 c Includes patients with baseline NAPSI score or ScPGA 1 d Includes patients with baseline ScPGA score 1 Error bars represent 95% CIs APR/APR (n=88)
34 Patients (%) Patients(%) CIMPASI-1 and CIMPASI-2: Maintenance of response with certolizumab pegol during 32-week rerandomized maintenance period PASI 75 (baseline to Week 48) PGA /1 (baseline to Week 48) PASI 9 (baseline to Week 48) CIMPASI-1 Placebo (n=51) CZP 2 mg q2w (n=95) CZP 4 mg q2w (n=88) * * * * 75.8% 66.5% 6.5% % 67.2% % * * * * 47.% * 4.2% % 52.7% % * * 35.8%.4% % 42.8% 48 CIMPASI-2 Placebo (n=49) CZP 2 mg q2w (n=91) CZP 4 mg q2w (n=87) * * 82.6% 81.4% 11.6% Week 81.3% 78.7% * * 71.6% 66.8% 2.% Week 72.6% 66.6% % * * 52.6% * 4.5% Week 62.% 59.6% 48 *P<.5, P<.1 vs placebo, based on logistic regression model with factors for treatment, region and prior biologic exposure (yes/no). Week 16 PASI 5 nonresponders were imputed as nonresponders throughout maintenance period; all other missing data were imputed via multiple imputation (Markov chain Monte Carlo [MCMC] method). CZP 2 mg q2w patients received loading dose of 4 mg at Weeks, 2 and 4 Reich K, et al. EADV 217, P1973 Sponsored by Dermira Inc. in collaboration with UCB Pharma
35 CIMPACT: Maintenance of response with certolizumab pegol during 32-week rerandomized maintenance period Patients (%) Patients (%) Patients (%) CZP 2 mg q2w CZP 4 mg q2w PASI % 46% Placebo q2w (n=22) CZP 2 mg q2w (n=44) CZP 4 mg q4w (n=44) Placebo q2w (n=25) CZP 2 mg q2w (n=5) CZP 4 mg q2w (n=49) 89% % 8% 36% PGA /1 PASI % 61% 14% % 61% % 64% 12% 48 88% 6% Week Week % Week Week 48 12% Missing data were imputed using NRI Augustin M, et al. EADV 217, P1969 Sponsored by Dermira Inc. in collaboration with UCB Pharma
36 CRIB: Maternal and infant plasma and umbilical cord levels of certolizumab pegol CZP concentration ( g/ml) CZP concentration ( g/ml) 1 Plasma CZP levels (n=14 mother infant pairs a ) Mothers Infants 1 Plasma CZP levels in umbilical cord (n=15 c ) Mothers Infants Umbilical cord infant had minimal CZP level of.42 μg/ml, mother s level was 49.4 μg/ml (infant/mother ratio:.9) 1 The infant with a CZP level at birth of.42 μg/ml had a CZP level of.4 μg/ml in the umbilical cord.1.1 LLOQ =.32 g/ml LLOQ =.32 g/ml BLQ Delivery Week 4 Week 8 (±24 hours) (±7 days) b (±7 days) BLQ Delivery Umbilical (±24 hours) cords d a 2/16 infant samples excluded from per protocol analysis set (1 missing data at birth, 1 due to implausible PK data [ie, data not consistent with pediatric CZP PK model, based on expected range of clearance, volume of distribution, and subsequent elimination t ½ ]); b 2 samples not collected; c 1 umbilical cord excluded due to missing data; d Umbilical cords were collected within 1 h of delivery. BLQ, below limits of quantitation of the assay; LLOQ, lower limit of quantitation Kimball A, et al. EADV 217, FC4.3 Sponsored by UCB Pharma
37 Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. N Engl J Med ;377:
38
39 First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. Br J Clin Pharmacol. 217;83(5):
40
41
42 RISANKIZUMAB
43
44 P456 Safety, efficacy and PK of a p19-directed IL-23 antibody (LY374828) in patients with plaque psoriasis and healthy subjects MIRIKIZUMAB Phase 1, placebo-controlled, 4 patients, 5 healthy volunteers, 12 weeks; 4% BSA, PASI 6.6 Another a p19-directed IL-23 antibody effective in phase 1 Tuttle J, et al. EADV 216, P456 Sponsored by Eli Lilly and Company 45
Biologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationWhat s New in Medical Dermatologic Therapy
What s New in Medical Dermatologic Therapy Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationPsoriasis Pearls. Mark Lebwohl, MD
Psoriasis Pearls Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Psoriasis Pearls Pearl #1 Patients who can
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationBiologics in Psoriasis: 2018 and Beyond. Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research
Biologics in Psoriasis: 218 and Beyond Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Biologics in Psoriasis FDA approved TNF inhibitors Etanercept Adalimumab
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationGaps in the Treatment of Psoriasis and PsA for Systemic Therapy
Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationPoster presented on Sunday 05 March, 14:50 14:55; 2017 AAD Meeting, Orlando, Florida, USA
Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: an Analysis of a Phase 3 Extension Trial in Psoriasis A Blauvelt 1, K Reich 2, RB Warren 3, B Sigurgeirsson 4, RG Langley 5, C Papavassilis
More informationAtopic Derma--s & Psoriasis Highlights. Ian McDonald Dermatology SpR
Atopic Derma--s & Psoriasis Highlights Ian McDonald Dermatology SpR Atopic derma66s Pathophysiology Associated morbidity Topical therapy Systemic therapy Crisaborole PDE4 inhibitor Primary endpoint: Success
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationIL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future
IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future This symposium took place on 13 th September 2018, as part of the 27 th European Academy of Dermatology and Venereology (EADV) Congress
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationIxekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι
Ixekizumab Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A Απρίλιοσ 218 ΕΠΕΜΥ Πόρτο Χέλι ΣΑΜΑΣΗ-ΝΙΚΟ ΛΙΟΗ Καθηγ. Ρευματολογίας Ιατρική χολή Παν. Πατρών Ixekizumab Στοιχεία για το mab
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationBody Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab
Am J Clin Dermatol (16) 17:691 699 DOI 1.7/s257-16-229-x ORIGINAL RESEARCH ARTICLE Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab April
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationICER Public Meeting: Evaluating Emerging Therapies for Psoriasis and Endometriosis
ICER Public Meeting: Evaluating Emerging Therapies for Psoriasis and Endometriosis July 12, 2018 WIFI Network: Student Password: [Open network] Targeted Immunomodulators for Plaque Psoriasis: Effectiveness
More informationPsoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationTargeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Background and Scope January 9, 2018 Background Psoriasis is a common
More informationEvaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes
Evaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes Faculty William J. Cardarelli, PharmD Director of Pharmacy Revenue and Supply Atrius Health
More informationPharmacy Accreditation
EASING THE PATIENT BURDEN OF PSORIASIS AND PSORIATIC ARTHRITIS: THE ROLE OF THE SPECIALTY PHARMACIST Claire Lee, PharmD, CSP, CPHQ Clinical Quality Improvement Supervisor Diplomat Flint, Michigan Pharmacy
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationWhat's Now, What's Next: Individualizing the Treatment of Patients With Moderate to Severe Psoriasis for the Dermatologist Presentation 1
The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants from Celgene
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.13216 JEADV SHORT REPORT HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationWhen researchers discovered in 1979 that the immunosuppressant
The Evolving Landscape of Psoriasis Treatment April W. Armstrong, MD, MPH,* Kenneth B. Gordon, MD, M. Alan Menter, MD, and Jashin J. Wu, MD Abstract The process of discovering new drugs for plaque psoriasis
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationPsoriasis: Which Drug for Which Patient? Mark Lebwohl, MD
Psoriasis: Which Drug for Which Patient? Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai DRUG PsA
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationThe 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909
The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 2-24, 215 Poster ID: 99 Clinical Efficacy and Safety of Brodalumab (KHK4827), Anti-Interleukin-17-Receptor A Fully
More informationKim A. Papp, MD PhD Probity Medical Research, Waterloo, ON, Canada
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pooled Efficacy Results from the Subgroup of Canadian Patients in Two Phase III Randomized Controlled
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationTranslating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment
Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment This symposium took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationEfficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Rheumatol Ther (2018) 5:567 582 https://doi.org/10.1007/s40744-018-0131-5 ORIGINAL RESEARCH Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies Peter
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 10 Last Review Date: June 22, 2018 Enbrel Description Enbrel (etanercept),
More informationContinuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
DOI: 1.1111/jdv.14163 JEADV ORIGINAL ARTICLE Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis A. Blauvelt, 1, * K.A.Papp, 2 H. Sofen,
More informationSource: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California
Source: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California OVERVIEW Steven R. Feldman, MD, PhD, and Alan Menter, MD, as well as principal investigators,
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add? CLINICAL TRIAL
CLINICAL TRIAL BJD British Journal of Dermatology Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab R.B. Warren,
More informationCost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis
1108 Cost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis Steven R. Feldman, MD, PhD 1 ; Tom Tencer, PhD 2 ; Zoe Clancy, PharmD,
More informationEmerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis These posters were presented at the 5 th World Psoriasis & Psoriatic Arthritis Conference 2018, held from 27 th 30 th June in Stockholm,
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationOverview of the Last Decade Inflammatory Skin Diseases. Mark Lebwohl, MD
Overview of the Last Decade Inflammatory Skin Diseases Mark Lebwohl, MD ProfessorAnd Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationSubject: Guselkumab (Tremfya ) Injection
09-J2000-87 Original Effective Date: 09/15/17 Reviewed: 09/12/18 Revised: 01/01/19 Subject: Guselkumab (Tremfya ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationSubject: Ixekizumab (Taltz ) Injection
09-J2000-62 Original Effective Date: 06/15/16 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Ixekizumab (Taltz ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationTopical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar
Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar Dr. Steven Feldman 1 Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands
More informationRegulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:
More informationRESEARCH. What is already known about this subject. What this study adds
RESEARCH Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database Steven R. Feldman, MD,
More informationPharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 10.1111/jdv.13990 JEADV ORIGINAL ARTICLE Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationPsoriasis Patients with: Integrating New Psoriasis Therapies Into Your Practice
Integrating New Psoriasis Therapies Into Your Practice Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology The Mount Sinai School of Medicine Psoriasis Patients with: Psoriatic
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TALTZ ixekizumab Solution for Injection 80 mg / 1.0 ml Immunomodulator Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8
More informationBiologic Therapy in Psoriasis: Navigating the Options
CLINICAL REVIEW Biologic Therapy in Psoriasis: Navigating the Options Cather McKay, MD; Katherine E. Kondratuk, BS; John P. Miller, BS; Brittany Stumpf, MD; Erin Boh, MD, PhD PRACTICE POINTS Psoriasis
More informationSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
BioDrugs (2015) 29:327 339 DOI 10.1007/s40259-015-0144-3 REVIEW ARTICLE Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast Melinda Gooderham 1,3 Kim Papp 2,3 Published online: 19
More informationHimmelfarb Health Sciences Library, The George Washington University. Dermatology Faculty Publications
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Dermatology Faculty Publications Dermatology 3-1-2017 The Efficacy and Safety of, and in Patients with
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationSYNOPSIS. Issue Date: 17 Jan 2013
STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More information4/10/18. Faculty. Disclosures. Confronting Psoriatic Disease: Putting New Tools to Work
Confronting Psoriatic Disease: Putting New Tools to Work Faculty Brad P. Glick, DO, MPH, FAOCD Glick Skin Institute Skin and Cancer Associates Program Director Dermatology Residency Larkin Hospital - Palm
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationADDITIONAL RESOURCES
ADDITIONAL RESOURCES CURRENT MODEL OF PSORIASIS IMMUNOPATHOGENESIS IL-17 A/FIL-22 GM-CSF Stressed keratinocytes TNF-α Myeloid dendritic cell Keratinocytes Activation IL-23 IL-12 T cells IL-1 BIL-6 TNF-α
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationDrug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More information